Summit Therapeutics Gets a Buy Rating from Oppenheimer

In a report released yesterday, Hartaj Singh from Oppenheimer maintained a Buy rating on Summit Therapeutics (NASDAQ: SMMT), with a price target of $30. The company’s shares closed on Friday at $12.20. More »

Analysts’ Opinions Are Mixed on These Healthcare Stocks: BioMarin (NASDAQ: BMRN), Oxford Immunotec (NASDAQ: OXFD) and Exact Sciences (NASDAQ: EXAS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioMarin (NASDAQ: BMRN), Oxford Immunotec (NASDAQ: OXFD) and Exact Sciences (NASDAQ: EXAS). BioMarin (NASDAQ: BMRN) In a More »